Screener
Monte Rosa Therapeutics, Inc. GLUE Return on invested capital
Return on invested capital at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s return on invested capital?
- Monte Rosa Therapeutics, Inc. (GLUE) reported return on invested capital of -53.9% in Q2 2026.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s return on invested capital?
- Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s return on invested capital has grown at a -15.5% compound annual growth rate (CAGR), from -82.5% to -59%.
- What does return on invested capital mean?
- Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.
Ask your AI about Monte Rosa Therapeutics, Inc.'s return on invested capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude